상세 보기
First-line (1L) trastuzumab deruxtecan (T-DXd)-based regimens in advanced HER2-expressing gastric cancer (GC), gastroesophageal junction adenocarcinoma (GEJA), or esophageal adenocarcinoma (EA): Safety results from DESTINY-Gastric03 (DG-03) Part 2 arms D and F, and Part 4.
- Janjigian, Yelena Y.;
- Shoji, Hirokazu;
- Kowalczyk, Anna;
- Rha, Sun Young;
- Pietrantonio, Filippo;
- ... Lee, Jeeyun;
- 외 14명
Citations
WEB OF SCIENCE
0- 제목
- First-line (1L) trastuzumab deruxtecan (T-DXd)-based regimens in advanced HER2-expressing gastric cancer (GC), gastroesophageal junction adenocarcinoma (GEJA), or esophageal adenocarcinoma (EA): Safety results from DESTINY-Gastric03 (DG-03) Part 2 arms D and F, and Part 4.
- 저자
- Janjigian, Yelena Y.; Shoji, Hirokazu; Kowalczyk, Anna; Rha, Sun Young; Pietrantonio, Filippo; Shitara, Kohei; Calvo Ferrandiz, Aitana; Van Laarhoven, Hanneke W. M.; Liu, Tianshu; Karaszewska, Boguslawa; Lee, Keun-Wook; Abdalla, Kathia Cristina; Chen, Eric Xueyu; Asselah, Jamil; Limon, M. Luisa; Scott, Megan; Lloyd, Caron; Nwazue, Eric; Rabbie, Roy; Lee, Jeeyun
- 발행일
- 2026-06-01
- 유형
- Meeting Abstract
- 권
- 44
- 호
- 16_SUPPL
- 언어
- ENG
- 출판사
- LIPPINCOTT WILLIAMS & WILKINS
- 발행국가
- 미국
- ISSN
- E 1527-7755
P 0732-183X